Poly Medicure Ltd Share Price – NSE /  BSE

Healthcare, Small Cap

Poly Medicure has appointed Indranil Mukherjee as Chief Executive Officer - Asia Pacific and India Business, Senior Management Personnel with effect from 01 June 2026.

Poly Medicure announced that the Board of Directors of the Company at its meeting held on 25 May 2026, inter alia, have recommended the final dividend of Rs 3.5 per equity Share (i.e. 70%) , subject to the approval of the shareholders.

Profit before tax (PBT) increased 30.63% YoY to Rs 85.22 crore in Q4 FY26.

Operating EBITDA dropped 8% to Rs 112.1 crore in Q4 FY26 from Rs 121.9 crore posted in Q4 FY25. EBITDA margin contracted to 667 bps to 21% in Q4 FY26 as against 27.6% in Q4 FY25.

Revenue from infusion therapy segment rose 1.9% YoY to Rs 256.1 crore while revenue from renal segment climbed 21.3% YoY to Rs 56.2 crore and revenue from others segment stood at Rs 222.1 crore, up 55.2% YoY.

On full year basis, the company?s consolidated net profit fell 4.85% to Rs 322.13 crore on 12.3% increase in revenue from operations to Rs 1,875.25 crore in FY26 over FY25.

Meanwhile, the company?s board recommended a dividend of Rs 3.5 per equity shares of Rs 5 each for the financial year 2025-26.

Poly Medicure exports plastic medical disposables/surgical devices. It manufactures and supplies approximately 100 types of disposable medical devices in the product verticals of infusion therapy, anesthesia, urology, gastroenterology, blood management and blood collection, surgery and wound drainage, dialysis and central venous access catheters.

Powered by Capital Market - Live News

Net profit of Poly Medicure declined 27.81% to Rs 66.29 crore in the quarter ended March 2026 as against Rs 91.83 crore during the previous quarter ended March 2025. Sales rose 21.25% to Rs 534.51 crore in the quarter ended March 2026 as against Rs 440.83 crore during the previous quarter ended March 2025.

For the full year,net profit declined 4.85% to Rs 322.14 crore in the year ended March 2026 as against Rs 338.56 crore during the previous year ended March 2025. Sales rose 12.30% to Rs 1875.26 crore in the year ended March 2026 as against Rs 1669.83 crore during the previous year ended March 2025.

Powered by Capital Market - Live News